《大行報告》瑞信上調中國銀河(06881.HK)目標價至5.6元 評級「跑贏大市」
瑞信發表報告指,其覆蓋研究的A股及H股雙重上市中資券商,在今年3月的純利按年及按月分別錄得32.9%及12.9%下跌,相信主要受投資收入低迷及經紀費用溫和放緩影響。
該行預期,將有很多中資券商於今年首季錄得純利增長,特別是行業龍頭如中信証券(06030.HK)及華泰證券(06886.HK),並相信內地券商行業仍直接受惠於資本市場進一步改革,及未來的貨幣政策支持。
瑞信上調對中國銀河(06881.HK)股份目標價,由5.5元升至5.6元,評級維持「跑贏大市」,並上調集團今明兩年盈利預測3.2%及0.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.